Key Points
- Director James Mulay sold 1,964 shares on March 16 at an average price of $63.50 for $124,714, and had earlier sold 11,145 shares on Jan. 9 at $52.47, signaling notable insider selling activity.
- Shares of CG Oncology are trading near their 52-week high (opened $68.64, 52‑week high $69.35) with a market capitalization of about $5.8 billion and a 50‑day moving average of $55.74, reflecting recent price strength.
- Wall Street and institutions are broadly bullish—multiple firms have raised price targets (Goldman $82, HC Wainwright $80, Piper $70) with a consensus target of $69, while large investors like Wellington and T. Rowe have materially increased stakes, leaving 26.56% of the stock owned by institutions.
CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director James Mulay sold 1,964 shares of the company's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $63.50, for a total transaction of $124,714.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
James Mulay also recently made the following trade(s):
- On Friday, January 9th, James Mulay sold 11,145 shares of CG Oncology stock. The shares were sold at an average price of $52.47, for a total transaction of $584,778.15.
CG Oncology Price Performance
Shares of CG Oncology stock opened at $68.64 on Wednesday. The company's 50 day moving average price is $55.74 and its two-hundred day moving average price is $45.40. The firm has a market capitalization of $5.80 billion, a P/E ratio of -33.16 and a beta of 1.17. CG Oncology, Inc. has a fifty-two week low of $14.80 and a fifty-two week high of $69.35.
CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings results on Friday, February 27th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.10. The company had revenue of $2.32 million for the quarter. On average, analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on CGON shares. Piper Sandler upped their target price on CG Oncology from $55.00 to $70.00 and gave the stock an "overweight" rating in a report on Friday, January 16th. HC Wainwright lifted their price target on CG Oncology from $75.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, February 27th. Wedbush started coverage on CG Oncology in a report on Thursday, December 11th. They set an "outperform" rating and a $70.00 price target on the stock. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $82.00 price objective on shares of CG Oncology in a research note on Monday, January 12th. Finally, Royal Bank Of Canada raised their price objective on shares of CG Oncology from $61.00 to $73.00 and gave the company an "outperform" rating in a report on Wednesday, January 21st. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, CG Oncology presently has an average rating of "Moderate Buy" and a consensus target price of $69.00.
Read Our Latest Report on CG Oncology
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Wellington Management Group LLP lifted its holdings in CG Oncology by 190.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company's stock worth $222,055,000 after buying an additional 3,613,885 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of CG Oncology by 116.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company's stock valued at $142,961,000 after buying an additional 1,854,386 shares during the period. Seven Fleet Capital Management LP acquired a new stake in shares of CG Oncology in the fourth quarter valued at about $62,909,000. Bank of America Corp DE raised its position in shares of CG Oncology by 409.9% during the second quarter. Bank of America Corp DE now owns 1,736,769 shares of the company's stock worth $45,156,000 after acquiring an additional 1,396,170 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of CG Oncology by 46.4% in the fourth quarter. State Street Corp now owns 2,996,695 shares of the company's stock worth $124,423,000 after acquiring an additional 950,028 shares during the period. 26.56% of the stock is owned by institutional investors.
About CG Oncology
(
Get Free Report)
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.
Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
